Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis

Abstract

Meningoencephalitis and DRESS may occur with daclizumab therapy. This potential lethal side effect is characterized by a dysregulated immune response. Our findings underline the importance of postmarketing drug surveillance.